Request Demo
Recent blog posts
Latest Hotspot
8 min read
Synovial sarcoma Indication Strategy Report 2026: EZH2, Trials and Deals
21 July 2026
Synovial sarcoma indication strategy report covering epidemiology, EZH2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Chondrosarcoma Indication Strategy Report 2026: IDH1, Trials and Deals
21 July 2026
Chondrosarcoma indication strategy report covering epidemiology, IDH1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Chordoma Indication Strategy Report 2026: TBXT, Trials and Deals
21 July 2026
Chordoma indication strategy report covering epidemiology, TBXT biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Sinonasal undifferentiated carcinoma Indication Strategy Report 2026: IDH2, Trials and Deals
21 July 2026
Sinonasal undifferentiated carcinoma indication strategy report covering epidemiology, IDH2 biology, active trials, competition and deal signals using PatSnap...
Latest Hotspot
8 min read
Laryngeal squamous cell carcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
21 July 2026
Laryngeal squamous cell carcinoma indication strategy report covering epidemiology, EGFR biology, active trials, competition and deal signals using PatSnap MCP...
Latest Hotspot
8 min read
Oropharyngeal squamous cell carcinoma Indication Strategy Report 2026: PD-1, Trials and Deals
21 July 2026
Oropharyngeal squamous cell carcinoma indication strategy report covering epidemiology, PD-1 biology, active trials, competition and deal signals using PatSnap...
Latest Hotspot
8 min read
Oral squamous cell carcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
21 July 2026
Oral squamous cell carcinoma indication strategy report covering epidemiology, EGFR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Salivary duct carcinoma Indication Strategy Report 2026: HER2, Trials and Deals
21 July 2026
Salivary duct carcinoma indication strategy report covering epidemiology, HER2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Adenoid cystic carcinoma Indication Strategy Report 2026: MYB, Trials and Deals
21 July 2026
Adenoid cystic carcinoma indication strategy report covering epidemiology, MYB biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Endometrial stromal sarcoma Indication Strategy Report 2026: ERα, Trials and Deals
21 July 2026
Endometrial stromal sarcoma indication strategy report covering epidemiology, ERα biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Uterine leiomyosarcoma Indication Strategy Report 2026: ERα, Trials and Deals
21 July 2026
Uterine leiomyosarcoma indication strategy report covering epidemiology, ERα biology, active trials, competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
8 min read
Mucinous ovarian carcinoma Indication Strategy Report 2026: KRAS, Trials and Deals
21 July 2026
Mucinous ovarian carcinoma indication strategy report covering epidemiology, KRAS biology, active trials, competition and deal signals using PatSnap MCP evidence.